CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger Sells 2,850 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This represents a 3.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $43.49 on Thursday. The company has a market capitalization of $3.73 billion, a PE ratio of -9.95 and a beta of 1.77. The company has a 50-day simple moving average of $43.02 and a two-hundred day simple moving average of $45.65. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $76.86.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of the company. Wood Tarver Financial Group LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $30,000. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. Ameriflex Group Inc. purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $36,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $43,000. Finally, Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CRSP. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a research note on Wednesday, February 12th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Bank of America dropped their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. The Goldman Sachs Group dropped their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.